About Transplant Genomics
Transplant Genomics is a company based in Los Angeles (United States) founded in 2013 was acquired by Eurofins Scientific in June 2019. It operates as a HealthTech. Transplant Genomics has raised $20.6 million across 7 funding rounds from investors including Eurofins Scientific. Transplant Genomics offers products and services including TruGraf Kidney, OmniGraf Liver, and Eurofins TRAC Kidney dd-cfDNA. Transplant Genomics operates in a competitive market with competitors including MedGenome, Foundation Medicine, Personalis, Veritas Genetics and Oxford Immunotec, among others.
- Headquarter Los Angeles, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Eurofins Transplant Genomics
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$20.6 M (USD)
in 7 rounds
-
Latest Funding Round
$7.98 M (USD), Series A
Aug 24, 2018
- Investors
-
Employee Count
Employee Count
-
Acquired by
Eurofins Scientific
(Jun 25, 2019)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Transplant Genomics
Transplant Genomics offers a comprehensive portfolio of products and services, including TruGraf Kidney, OmniGraf Liver, and Eurofins TRAC Kidney dd-cfDNA. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Surveillance for subclinical acute rejection in kidneys is provided.
Immunosuppression optimization for liver transplant patients is offered.
Clinical acute rejection detection in kidneys is facilitated.
Unlock access to complete
Unlock access to complete
Funding Insights of Transplant Genomics
Transplant Genomics has successfully raised a total of $20.6M across 7 strategic funding rounds. The most recent funding activity was a Series A round of $7.98 million completed in August 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 7
- Last Round Series A — $8.0M
-
First Round
First Round
(04 Apr 2014)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2018 | Amount | Series A - Transplant Genomics | Valuation |
investors |
|
| Apr, 2017 | Amount | Series A - Transplant Genomics | Valuation |
investors |
|
| Feb, 2017 | Amount | Series A - Transplant Genomics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Transplant Genomics
Transplant Genomics has secured backing from 1 investor. Prominent investors backing the company include Eurofins Scientific. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Laboratory testing and contract research services are provided globally.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Transplant Genomics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Transplant Genomics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Transplant Genomics Comparisons
Competitors of Transplant Genomics
Transplant Genomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as MedGenome, Foundation Medicine, Personalis, Veritas Genetics and Oxford Immunotec, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
DNA sequencing, bioinformatics, and multiomics services are provided.
|
|
| domain | founded_year | HQ Location |
Genomics-based diagnostic tests for cancer are provided.
|
|
| domain | founded_year | HQ Location |
Genomic sequencing and diagnosis software is provided for healthcare.
|
|
| domain | founded_year | HQ Location |
Genetic testing products for health risks and traits are offered.
|
|
| domain | founded_year | HQ Location |
Immune markers are utilized by Oxford Immunotec for disease diagnostics.
|
|
| domain | founded_year | HQ Location |
Personalized cancer diagnostics are developed using genomic big data analysis.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Transplant Genomics
Frequently Asked Questions about Transplant Genomics
When was Transplant Genomics founded?
Transplant Genomics was founded in 2013 and raised its 1st funding round 1 year after it was founded.
Where is Transplant Genomics located?
Transplant Genomics is headquartered in Los Angeles, United States. It is registered at Los Angeles, California, United States.
Who is the current CEO of Transplant Genomics?
Stanley Rose is the current CEO of Transplant Genomics.
Is Transplant Genomics a funded company?
Transplant Genomics is a funded company, having raised a total of $20.6M across 7 funding rounds to date. The company's 1st funding round was a Series A of $1.71M, raised on Apr 04, 2014.
What does Transplant Genomics do?
Molecular diagnostic tests are provided by Eurofins Transplant Genomics to improve organ transplant outcomes. Early signs of graft injury are detected, actionable causes are differentiated, and therapy optimization is enabled. Focus is placed on kidney and liver transplantation with tests like TruGraf Kidney and OmniGraf Liver. The healthcare sector, specifically biotechnology and molecular diagnostics, is served through genetic biomarker-guided solutions.
Who are the top competitors of Transplant Genomics?
Transplant Genomics's top competitors include Foundation Medicine, MedGenome and Personalis.
What products or services does Transplant Genomics offer?
Transplant Genomics offers TruGraf Kidney, OmniGraf Liver, and Eurofins TRAC Kidney dd-cfDNA.
Who are Transplant Genomics's investors?
Transplant Genomics has 1 investor. Key investors include Eurofins Scientific.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.